Published in Vaccine Weekly, April 5th, 2006
"A double-inactivated candidate whole virus vaccine against severe acute respiratory syndrome associated coronavirus (SARS-CoV) was developed and manufactured at large scale using fermenter cultures of serum protein free Vero cells. A two-step inactivation procedure involving sequential formaldehyde and UV inactivation was utilized in order to ensure an extremely high safety margin with respect to residual infectivity. The immunogenicity of this double-inactivated vaccine was characterized in the mouse model," scientists writing in the journal Vaccine report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly